Application Note: Kinetic degradation of IMiD molecular glues and their target families
23 February 2023

In this application note, Agilent outlines the automation of parallel degradation and viability screening of several key immunomodulatory drug (IMiD) molecular glue targets, IKZF1 (Ikaros), GSPT1, and IKZF2 (Helios) with various IMiDs using the Promega Nano-Glo® HiBiT technology, in conjunction with the Agilent BioTek BioSpa 8 automated incubator and the Agilent BioTek Synergy Neo2 hybrid multimode reader. Targeted protein degradation of disease-causing proteins has proven to be a powerful therapeutic approach. The ability to monitor the specificity of degradation amongst related target classes at endogenous protein levels, continuously in live cells, is critical for understanding the efficacy and mechanism of these compounds.